Przejdź do zawartości
Merck

Kluczowe dokumenty

Wyświetl całą dokumentację

Przejdź do

5.32978

PLD2 Inhibitor, ML395

Synonim(y):

PLD2 Inhibitor, ML395, Phosppolipase D2 inhibitor, VU0468809, ML-395

Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

Zmień widok
Gabaryty przesyłkiSKUDostępnośćCena netto
10 mg
Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności
979,00 zł

Informacje o tej pozycji

Wzór empiryczny (zapis Hilla):
C26H29N5O2
Numer CAS:
1638957-17-1
Masa cząsteczkowa:
443.54
MDL number:
MFCD28502199
NACRES:
NA.77
UNSPSC Code:
12352200
Assay:
≥97% (HPLC)
Form:
solid
Quality level:
100
Storage condition:
OK to freeze, protect from light

979,00 zł

Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności
​
Zamów zamówienie zbiorcze
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc

assay

≥97% (HPLC)

Quality Level

100

form

solid

potency

360 nM IC50

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

off-white

solubility

DMSO: 50 mg/mL

storage temp.

2-8°C

General description

A cell permeable, triazaspirone derivative that acts as a highly potent, selective, and direct allosteric inhibitor of phospholipase D2 (PLD2; IC50 = 360 nM in exogenous biochemical assay). Exhibits >80-fold selectivity over phospholipase D1 (PLD1; IC50 = 30 µM). Shown to permeate the blood-brain barrier. Protects A549 cells from multiple strains of influenza virus when cells were pre-treated with this compound. Exhibits excellent DMPK profile (hepatic microsomal clearance = 82.1 ml/min/kg in Sprague-Dawley rats) and conforms to Lipinski′s rule and has favorable lipophilicity. Also displays favorable cytochrome P450 profile (CYP3A4 IC50 = 3.9 µM, CYP2D6 IC50 =16.4 µM, CYP1A2 IC50>30 µM, and CYP2C9 IC50>30 µM).
ML395 is a cell permeable, highly potent, selective, and direct allosteric inhibitor of phospholipase D2 (PLD2; IC₅₀ = 360 nM) that exhibits >80-fold selectivity over PLD1.

Biochem/physiol Actions

Primary Target
PLD2
Reversible: yes

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C).

Other Notes

O′Reilly, M.C., et al. 2014. ChemMedChem9, 2633.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)
Ta strona może zawierać tekst przetłumaczony maszynowo.

Porównaj podobne pozycje

Wyświetl pełne porównanie

Pokaż różnice

1 of 1

Ta pozycja
5282455.32910WH0005338M1
PLD2 Inhibitor, ML395

Sigma-Aldrich

5.32978

PLD2 Inhibitor, ML395

PLD Inhibitor, FIPI The PLD Inhibitor, FIPI controls the biological activity of PLD. This small molecule/inhibitor is primarily used for Membrane applications.

Sigma-Aldrich

528245

PLD Inhibitor, FIPI

Sigma-Aldrich

Sigma-Aldrich

5.32910

TrxR Inhibitor, D9

Monoclonal Anti-PLD2 antibody produced in mouse clone 1C5, purified immunoglobulin, buffered aqueous solution

Sigma-Aldrich

WH0005338M1

Monoclonal Anti-PLD2 antibody produced in mouse

form

solid

form

powder

form

solid

form

buffered aqueous solution

assay

≥97% (HPLC)

assay

≥99% (HPLC)

assay

≥98% (HPLC)

assay

-

manufacturer/tradename

Calbiochem®

manufacturer/tradename

Calbiochem®

manufacturer/tradename

Calbiochem®

manufacturer/tradename

-

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

−20°C

storage temp.

−20°C

storage condition

OK to freeze, protect from light

storage condition

OK to freeze, protect from light

storage condition

OK to freeze, protect from light

storage condition

-

Klasa składowania

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Powiązane treści

Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System

A major focus of breast cancer research is to understand the mechanisms responsible for disease progression and drug resistance. Toward that end, it has been found that approximately two thirds of all human breast carcinomas overexpress the Estrogen Receptor α (ERα) protein and it remains the primary pharmacological target for endocrine therapy1,2. The normal cellular function of ERα is as a transcription factor that mediates a wide variety of physiological processes, many of which are dependent upon phosphorylation of the receptor at specific amino acid residues3,4. Indeed, ERα is known to be phosphorylated at a multitude of different sites, yet how these all correlate to disease remains unclear5. Here, we interrogated multiple sites of ERα for phosphorylation status by screening an extensive panel of different breast cancer patient samples and other non-breast cancer tissue microarray (TMA) slide samples to determine their relevance to disease.

Numer pozycji handlu globalnego

SKUNUMER GTIN
532978000104055977281972

Questions

Reviews

No rating value

Active Filters